Mortality in heroin users 3 years after naltrexone implant or methadone maintenance treatment

Concerns that treatment for heroin dependence using naltrexone may increase suicide rates during treatment and fatal overdoses posttreatment have been expressed. There is also disquiet about mortality during induction onto methadone. We assessed mortality during specific periods following treatment...

Full description

Bibliographic Details
Main Authors: Tait, Robert, Ngo, H., Hulse, G.
Format: Journal Article
Published: 2008
Online Access:http://hdl.handle.net/20.500.11937/34111
_version_ 1848754133673181184
author Tait, Robert
Ngo, H.
Hulse, G.
author_facet Tait, Robert
Ngo, H.
Hulse, G.
author_sort Tait, Robert
building Curtin Institutional Repository
collection Online Access
description Concerns that treatment for heroin dependence using naltrexone may increase suicide rates during treatment and fatal overdoses posttreatment have been expressed. There is also disquiet about mortality during induction onto methadone. We assessed mortality during specific periods following treatment with naltrexone implants or methadone. Data were assembled using the Western Australian Data Linkage System. The methadone cohort comprised all those who started methadone in Western Australia during 2001-2002: The naltrexone cohort comprised all Western Australian heroin-dependent persons who received their first implant in 2001-2002. There were 15 (2.7%) deaths in the methadone cohort (n = 553) and 6 (1.8%) deaths in the naltrexone cohort (n = 341). Mortality rates for the "initial 14-day period," "stable treatment," and "overall" were 94.47, 0.0, and 5.83 deaths/1,000 person-years for the methadone group. In the naltrexone group, the rates "during first treatment (0-6 months)," "post first treatment," and overall were 0.0, 4.21, and 3.76 deaths/1,000 person-years. The age-standardized mortality rate ratio for naltrexone compared to methadone was 0.645 (95% confidence interval = 0.123-1.17). Increased mortality during induction onto methadone was confirmed. Evidence relating naltrexone to either increased suicide or overdose was not found. Overall mortality rates for naltrexone implant were similar to those for methadone, but increased mortality during methadone induction was avoided. © 2008 Elsevier Inc. All rights reserved.
first_indexed 2025-11-14T08:35:34Z
format Journal Article
id curtin-20.500.11937-34111
institution Curtin University Malaysia
institution_category Local University
last_indexed 2025-11-14T08:35:34Z
publishDate 2008
recordtype eprints
repository_type Digital Repository
spelling curtin-20.500.11937-341112017-09-13T15:08:56Z Mortality in heroin users 3 years after naltrexone implant or methadone maintenance treatment Tait, Robert Ngo, H. Hulse, G. Concerns that treatment for heroin dependence using naltrexone may increase suicide rates during treatment and fatal overdoses posttreatment have been expressed. There is also disquiet about mortality during induction onto methadone. We assessed mortality during specific periods following treatment with naltrexone implants or methadone. Data were assembled using the Western Australian Data Linkage System. The methadone cohort comprised all those who started methadone in Western Australia during 2001-2002: The naltrexone cohort comprised all Western Australian heroin-dependent persons who received their first implant in 2001-2002. There were 15 (2.7%) deaths in the methadone cohort (n = 553) and 6 (1.8%) deaths in the naltrexone cohort (n = 341). Mortality rates for the "initial 14-day period," "stable treatment," and "overall" were 94.47, 0.0, and 5.83 deaths/1,000 person-years for the methadone group. In the naltrexone group, the rates "during first treatment (0-6 months)," "post first treatment," and overall were 0.0, 4.21, and 3.76 deaths/1,000 person-years. The age-standardized mortality rate ratio for naltrexone compared to methadone was 0.645 (95% confidence interval = 0.123-1.17). Increased mortality during induction onto methadone was confirmed. Evidence relating naltrexone to either increased suicide or overdose was not found. Overall mortality rates for naltrexone implant were similar to those for methadone, but increased mortality during methadone induction was avoided. © 2008 Elsevier Inc. All rights reserved. 2008 Journal Article http://hdl.handle.net/20.500.11937/34111 10.1016/j.jsat.2007.08.014 restricted
spellingShingle Tait, Robert
Ngo, H.
Hulse, G.
Mortality in heroin users 3 years after naltrexone implant or methadone maintenance treatment
title Mortality in heroin users 3 years after naltrexone implant or methadone maintenance treatment
title_full Mortality in heroin users 3 years after naltrexone implant or methadone maintenance treatment
title_fullStr Mortality in heroin users 3 years after naltrexone implant or methadone maintenance treatment
title_full_unstemmed Mortality in heroin users 3 years after naltrexone implant or methadone maintenance treatment
title_short Mortality in heroin users 3 years after naltrexone implant or methadone maintenance treatment
title_sort mortality in heroin users 3 years after naltrexone implant or methadone maintenance treatment
url http://hdl.handle.net/20.500.11937/34111